Application of Metabolomics Approach to Study on Chemical Constituents in Cultivated and Wild Pinellia ternate (Thunb.) Breit. and Typhonium flagelliforme (Lodd.) Blume Based on UPLC-ESI-HRMS^n

[Objectives] The aim was to study chemical components of cultivated and wild Pinellia ternate(Thunb.) Breit and Typhonium flagelliforme(Lodd.) Blume by metabolomics technology based on UPLC-ESI-HRMS^n. [Methods] Chemical components of 27 samples of cultivated and wild P. ternate and T. flagelliforme were detected by using UPLC-ESI-HRMS^ntechnology. Differential markers between P. ternate and T. flagelliforme as well as cultivated and wild P. ternate were screened and identified by principal component analysis(PCA) and orthogonal partial least square-discriminate analysis(OPLS-DA). [Results]12 components of P. ternate(cultivated and wild variety) and T.flagelliforme and three components of cultivated and wild P. ternate were screened and identified by OPLS-DA. N-Acetyl-6-hydroxy-L-tryptophan and N-Phenylacetylglutamic were not detected in P. ternate,and these two components can be used as potential markers of P. ternate and T. flagelliforme. [Conclusions]UPLC-ESI-HRMS^n-based metabolomics technology could be used to quickly identify the chemical constituents of P. ternate and effectively distinguish P. ternate and T. flagelliforme,which has reference significance for the quality control of P. ternate.

The deubiquitinating enzyme 13 retards non-alcoholic steatohepatitis via blocking inactive rhomboid protein 2-dependent pathway

Nowadays potential preclinical drugs for the treatment of nonalcoholic steatohepatitis(NASH)have failed to achieve expected therapeutic efficacy because the pathogenic mechanisms are underestimated.Inactive rhomboid protein 2(IRHOM2),a promising target for treatment of inflammation-related diseases,contributes to deregulated hepatocyte metabolism-associated nonalcoholic steatohepatitis(NASH)progression.However,the molecular mechanism underlying Irhom2 regulation is still not completely understood.In this work,we identify the ubiquitin-specific protease 13(USP13)as a critical and novel endogenous blocker of IRHOM2,and we also indicate that USP13 is an IRHOM2-interacting protein that catalyzes deubiquitination of Irhom2 in hepatocytes.Hepatocyte-specific loss of the Usp13 disrupts liver metabolic homeostasis,followed by glycometabolic disorder,lipid deposition,increased inflammation,and markedly promotes NASH development.Conversely,transgenic mice with Usp13 overexpression,lentivirus(LV)-or adeno-associated virus(AAV)-driven Usp13 gene therapeutics mitigates NASH in 3 models of rodent.Mechanistically,in response to metabolic stresses,USP13 directly interacts with IRHOM2 and removes its K63-linked ubiquitination induced by ubiquitin-conjugating enzyme E2N(UBC13),a ubiquitin E2 conjugating enzyme,and thus prevents its activation of downstream cascade pathway.USP13 is a potential treatment target for NASH therapy by targeting the Irhom2 signaling pathway.